# CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

Source: https://onco.cc/trials/nct06420089/  
OnCo record `nct06420089` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Senza5 CART5 run by Vittoria Biotherapeutics, now recruiting.

## Summary

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) is a phase 1 interventional study registered as NCT06420089 by Vittoria Biotherapeutics, with 30 participants planned, started 2024-10-04. Conditions recorded: T Cell Non-Hodgkin Lymphoma. Interventions recorded: Senza5 CART5.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06420089
- Phase: 1
- Setting: CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial
- Sponsor: Vittoria Biotherapeutics
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT06420089: https://clinicaltrials.gov/study/NCT06420089

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Senza5 CART5](https://onco.cc/drugs/viper-101/)
- companies: [Vittoria Biotherapeutics](https://onco.cc/companies/vittoria-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06420089.json